Nancy Stagliano, Ph.D., is CEO and chair of the board of Neuron23, Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. An experienced CEO, Nancy has led True North Therapeutics (acquired by Bioverativ in 2017), iPierian (acquired by BMS in 2014), and CytomX Therapeutics. (CTMX). With nearly three decades’ experience in the biotechnology industry, Nancy’s career path has always stayed close to the science, beginning with more than seven years at Millennium Pharmaceuticals in Cambridge, MA, in the discovery organization.

Nancy is currently executive chair of the boards of Star and Electra Therapeutics, focused on orphan hematology indications. In addition, Nancy serves as chair of the board of Latigo Bio, a biotech focused on non-opioid pain medicines. Nancy also serves as a director on the not-for-profit board of the Pancreatic Cancer Action Network (PanCAN). In the past, Nancy has also advised venture capital firms Westlake Village BioPartners and New Leaf Ventures.

Nancy holds a Ph.D. in neuroscience from the University of Miami School of Medicine and a master’s degree in biomedical engineering from Drexel University.